Unravelling industry bias in clinical trials

Pain

Volumn 121, Issue 3, 2006, Pages 175-176

  Gluud, Lise Lotte ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; ROFECOXIB;

CLINICAL TRIAL; DRUG INDUSTRY; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEART INFARCTION; HUMAN; INFORMATION; MIGRAINE; PAIN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; THROMBOSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANALGESICS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; FINANCIAL SUPPORT; HUMANS; PAIN;

EID: 33645001809     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.01.001     Document Type: Editorial

References (11)

1. B. Als-Nielsen, W. Chen, C. Gluud, and L.L. Kjaergard Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? J Am Med Assoc 290 2003 921 928
2. J. Barden, S. Derry, H.J. McQuay, and A. Moore Bias from industry trial funding? A framework, a suggested approach, and a negative result Pain 121 2005 207 218
3. C. Begg, M. Cho, S. Eastwood, R. Horton, D. Moher, and I. Olkin Improving the quality of reporting of randomized controlled trials: the CONSORT statement J Am Med Assoc 276 1996 637 639
4. M. Bhandari, J.W. Busse, D. Jackowski, V.M. Montori, H. Schunemann, and S. Sprague Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials Can Med Assoc J 170 2004 477 480
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
6. G.D. Curfman, S. Morrissey, and J.M. Drazen Expression of Concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid arthritis N Engl J Med 343 2000 1520 1528 N Engl J Med. 2005;353:2813-4
7. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, T.V. Schroeder, H.C. Sox, M.B. Van Der Weyden and International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1.
8. De Angelis, J.M. Drazen, F.A. Frizelle, C. Haug, J. Hoey, R. Horton, S. Kotzin, C. Laine, A. Marusic, A.J. Overbeke, T.V. Schroeder, H.C. Sox, M.B. Van Der Weyden and International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-9.
9. L.L. Kjaergard, and C. Gluud Funding, disease area, and internal validity of hepatobiliary randomized clinical trials Am J Gastroenterol 97 2002 2708 2713
10. J. McCormack, and R. Rangno Digging for data from the COX-2 trials Can Med Assoc J 166 2002 1649 1650
11. D. Moher, K.F. Schulz, and D.G. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials Lancet 35 2001 1191 1194